The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy

Am J Hematol. 2022 Mar 1;97(3):E117-E120. doi: 10.1002/ajh.26449. Epub 2021 Dec 29.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Female
  • Humans
  • Life Expectancy*
  • Male
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / mortality*
  • Retrospective Studies

Substances

  • Antibodies, Monoclonal
  • daratumumab